Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 792

1.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

2.

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.

J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.

PMID:
13130113
3.

Radical prostatectomy for clinical stage T3a disease.

Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.

Cancer. 2007 Apr 1;109(7):1273-8.

4.

Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK; SEARCH Database Study Group.

Urology. 2003 Apr;61(4):742-7.

PMID:
12670558
5.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

PMID:
19858385
6.

Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.

Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L, Bostwick DG.

J Urol. 1999 Apr;161(4):1233-7.

PMID:
10081876
7.

Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.

Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll PR.

Urology. 2002 Apr;59(4):560-5.

PMID:
11927314
8.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.

Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.

9.
10.
12.
13.

Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.

Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML.

J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1. doi: 10.1016/j.juro.2007.11.061. Epub 2008 Mar 4.

PMID:
18289596
14.

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.

J Urol. 2007 Nov;178(5):1957-62; discussion 1962. Epub 2007 Sep 17.

PMID:
17868719
15.

Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.

Paparel P, Cronin AM, Savage C, Scardino PT, Eastham JA.

Eur Urol. 2009 Feb;55(2):404-10. doi: 10.1016/j.eururo.2008.07.007. Epub 2008 Jul 14.

PMID:
18639970
16.

Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?

Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2002 Dec;168(6):2510-5.

PMID:
12441951
17.
18.

Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.

Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML.

Cancer. 2002 Sep 1;95(5):1028-36.

19.
20.

Factors predicting prostatic biopsy Gleason sum under grading.

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW.

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

PMID:
19447436

Supplemental Content

Support Center